Nisa Investment Advisors
GALT icon

Nisa Investment Advisors’s Galectin Therapeutics GALT Stock Holding History

Nisa Investment Advisors’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.32K Hold
716
– – ﹤0.01% 2677
2026
Q1 		$2K Hold
716
– – ﹤0.01% 2615
2025
Q4 		$2.98K Hold
716
– – ﹤0.01% 2545
2025
Q3 		$3.03K Hold
716
– – ﹤0.01% 2538
2025
Q2 		$1.51K Hold
716
– – ﹤0.01% 2659
2025
Q1 		$874 Buy
+716
New +$1K ﹤0.01% 2671

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Nisa Investment Advisors's GALT Position: Q2 2026 in Review

Nisa Investment Advisors held its Galectin Therapeutics (GALT) position steady in Q2 2026 at 716 shares worth $3.32K. The position accounts for ﹤0.01% of the portfolio, ranked #2677.

Nisa Investment Advisors first reported a position in GALT in Q1 2025 and has held it in 6 quarters since. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • Nisa Investment Advisors held 716 shares of Galectin Therapeutics worth $3.32K as of Q2 2026.
  • Nisa Investment Advisors left its Galectin Therapeutics share count unchanged in Q2 2026.
  • Galectin Therapeutics made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #2677 holding.
  • Nisa Investment Advisors first reported a position in Galectin Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.